US Edition
Veterans' Groups, Lawmakers Applaud Fast-Track for Psychedelic Drug Reviews
The order directs federal agencies to speed reviews, ease research limits and provide $50 million in funding for psychedelic therapy studies.
- On Saturday, April 18, 2026, President Donald Trump signed an executive order aimed at accelerating clinical research and federal approval for psychedelic therapies, highlighting ibogaine as a priority for treating veteran mental health and substance use disorders.
- The order directs the FDA to prioritize psychedelic compound reviews, instructs the DEA to reduce research restrictions, and mandates $50 million in federal funding to match state-level research programs, marking a significant federal policy shift.
- KALA BIO, Inc. celebrated the policy shift, noting it strengthens the outlook for client Red Light Holland, while experts suggest ibogaine might temporarily re-open a "critical period" to help reset brain patterns in patients.
- The directive establishes expanded access pathways under the Right to Try Act, which Rachel Yehuda, a psychiatry specialist at the Icahn School of Medicine at Mount Sinai, said is "going to make things easier to advance psychedelic therapies."
- Researchers like Alan Davis of Ohio State University caution that ibogaine remains a Schedule I substance, currently lagging behind psilocybin and MDMA in the clinical approval process.
17 Articles
17 Articles
What to Know About Trump’s New Executive Order on Psychedelic Drugs
President Donald Trump speaks during an executive order signing regarding psychedelics in the Oval Office of the White House in Washington, DC, on April 18, 2026. —Allison Robbert for The Washington Post—Getty ImagesOn April 18, President Donald Trump signed an executive order intended to accelerate the development of psychedelic drugs as medical treatments. The order calls for the Food and Drug Administration (FDA) to give expedited considerati…
Explainer: What to know about psychedelic therapies cited by Trump
April 21 - U.S. President Donald Trump this week signed an executive order directing health regulators to speed reviews of psychedelic treatments and increase federal funding for research into their use in response to advocates for the drug ibogaine including influential podcaster Joe Rogan. Read more at straitstimes.com.
Trump Pushes for Federally-Approved Psychedelic Treatments
Photo: Trevor Hughes ~ USA TODAY NETWORK PODCAST: April 21, 2026 ~ Chris Renwick and Lloyd Jackson spoke with Melissa Lavasani, CEO of Psychedelic Medicine Coalition. They discussed the executive order fast-tracking psychedelic research for mental health, and the need for new healthcare infrastructure.WASHINGTON D.C. ~ President Donald Trump signed an executive order Monday to fast-track federal approvals to use certain psychedelic drug…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
